{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-271351","form_type":"8-K","ticker":"AURA","cik":"0001501796","company_name":"Aura Biosciences, Inc.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.285919+00:00","generated_at":"2026-06-08T19:46:23.385384+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Aura Biosciences Receives FDA SPA Agreement for CoMpass Phase 3 Trial of Bel-sar in Choroidal Melanoma","bullets":["FDA agreed under Special Protocol Assessment to design and planned analysis of CoMpass Phase 3 trial for bel-sar in early-stage choroidal melanoma.","Phase 2 data with 90% follow-up at 12 months showed 80% tumor control and 90% visual acuity preservation in patients meeting Phase 3 criteria.","Preliminary Phase 1 bladder cancer data: first patient with light activation achieved clinical complete response with extensive necrosis and immune activation.","Company terminated ATM equity offering program with Jefferies, suspending sales under existing prospectus."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-271351","json":"https://secwatch.observer/filing/0001193125-23-271351.json","markdown":"https://secwatch.observer/filing/0001193125-23-271351.md","text":"https://secwatch.observer/filing/0001193125-23-271351.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501796/000119312523271351/0001193125-23-271351-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501796/000119312523271351/d471944d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T19:46:23.385384+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}